Achieve Life Sciences (ACHV) Non-Current Deffered Revenue (2010 - 2011)
Achieve Life Sciences' (ACHV) quarterly Non-Current Deffered Revenue came in at $9.0 million in Q3 2011, down 8.41% on a QoQ basis from $9.9 million in Q2 2011.
Powered by 
Analysis
Achieve Life Sciences (ACHV) Non-Current Deffered Revenue (2010 - 2011) Analysis & Trends
Achieve Life Sciences (ACHV) has 2 years of Non-Current Deffered Revenue data on file, last reported at $9.0 million in Q3 2011.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $9.0 million in Q3 2011, while the trailing twelve-month figure through Sep 2011 was $9.0 million (changed N/A YoY) and the FY2010 annual result came in at $11.6 million, changed N/A from the prior year.
- Non-Current Deffered Revenue declined to $9.0 million in Q3 2011, from $9.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $11.6 million in Q4 2010 to a low of $9.0 million in Q3 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Achieve Life Sciences | 369.90 Mn | 369.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2011 | 9.04 Mn |
| Jun 30, 2011 | 9.87 Mn |
| Dec 31, 2010 | 11.62 Mn |